Member Info for PlantPower

....12.59...must be a but surely?

Go hard or go home DaveyBoy!

See the mattress has been flipped ;0)

Read in to what you will...might just be his friend ;0)

https://mobile.twitter.com/Moilgas/status/1303243611287556096/photo/1

https://mobile.twitter.com/Moilgas/status/1303242516997836800/photo/1

.....momentarily on bid and ask..!

robbing peter to pay paul ;0)

Blue coming??

Here here - we’ll said @Dave77.

Let’s get this done already!

PP

Someone really loaded - 100k & 27k vol @ £1 + 25k @97.99.....ouch today, hopefully immaterial next week.

Circa 75k vol delayed sells.

Expect as well as ODX, SP pressure due to some exiting post ‘leak’ rumour not coming true....blame Jay! ;0)

PP

Agreed @grimshady.

You’re a braver man than me if LTH and switch cabs at this juncture.

We’ve seen this before - blue finish??

Agree - if no update within that timeframe & ‘approx 6 week’ card played, then credibility takes a big hit.

So close to 6 week update (let alone FDA/Indian/WHO approvals) - interim market movement just a sideshow.

Eye on the prize.

#PeacePlantsPatience

https://www.bbc.co.uk/news/uk-54050342

Return to work / schools / university.....2nd wave incoming.

Experienced car park testing today - had to travel an hour for test - testing at breaking point, car park full, it’s going to get worse.

PP

I’ll go 3 dukdo’s upon BC validation...

Que???

GDR to help bring the Henry Ford mass productionisation to the Covid Testing assembly line...

....it’s coming!

PP

@Dave77 forgot to say earlier, agree with @invest4thelt, projections should be higher if BC tie up validated, there was also a lot a chat at the time that projections were conservative even pre-BC news.

If BC goes ahead - be interesting to see if BC / DIVOC tie up alone will saturate our capacity in short term and Africa may be on ice....would be nice problem to have.

Would like to know if we’ve been stockpiling pre news (and how many) - would need a big pellet warehouse if so, it’s been long enough! ;0)

PP

Note GHIF funding / investment (loan) was pre Covid & to fund Hep C virus diagnostic kit, now WHO approved, maybe view profits from Covid etc means GDR can self sustain investment to roll out in future off back off Covid gravy train / launch pad???

GHIF springboard no longer needed, capital could be leveraged elsewhere??

Appreciate above would mean GHIF have maximum confidence ahead of GDR monetising opportunity..,,

So maybe far fetched, plus, why not hang around for profits and build further good news successful philanthropic investment to help not only rollout HepC but Covid testing to Africa & India?

That’s me done!

PP

Last post, to clarify - POC yes in future / PCR slim chance due to Deloitte / PHE changes but unlikely in my view.

You never know - the only reason I still see future POC potential in NHS/PHE is Deloitte now in play:

https://www.opendemocracy.net/en/deloitte-gets-another-huge-covid-contract-for-crazy-plan-to-test-millions-each-day/

Plus replacement of PHE:

https://www.bmj.com/content/370/bmj.m3257

New plan / infrastructure required for mass accurate and timely testing.....outside chance GDR / BC could be asked to step-up (from memory posted previously Northumberland recently awarded small contract for some BC kit (?) - can’t remember if aligns with our setup)

bigAl - I don’t believe DB statement of year end included CE approval (def not others!), but expect it may end up that way.

PP

Ok - sitting in front of open fire with cider (why not) pondering II Seller (or short selling), and have a conspiracy theory.

@Dave77 highlighted it could be GHIF but I thought Calculus, but reviewing previous research, maybe that doesn’t stack up:

- Calculus (8.99% at last update) - per ‘results’ section they were happy to promote ‘Genedrive (May 2020) 2.1x return’ but that was selling circa 140+, so would they be comfortable with smaller returns (presuming chunk of shares from placement - maybe they bought earlier, haven’t checked back yet).

https://www.calculuscapital.com/what-we-do/

- Alternate is Spreadex (5.05%) - as impatience wears thin maybe those who took long positions expecting approvals are retreating.

But what about GHIF (13.66%)?:

- Longevity of II selling makes me question if GHIF are the only II with enough shares for prolonged selling without yet crossing 2.99% notification threshold.
- Selling initiated since BC RNS - has that changed the investabilty of GDR (Per below) - do we no longer meet GHIF primary criteria?
- Does GHIF feel GDR are now on their merry way & have potential large US Pharma tie up meaning funding no longer required?
- GDR still seem to clearly tick India box but maybe concern BC tie up will mean US will swallow up majority of production capability?

“ We only invest in companies developing innovative products that can be used in settings with limited resources. Much impactful and innovative medical technology is never brought to market outside of the US & Europe, because there’s generally going to be less of a financial reward for doing so. That’s where GHIF comes in. We identify high impact health outcomes, generally involving a new medical technology or drug. We then do two things:

Firstly, we screen whether the product serves a need in low-resource settings, like sub-Saharan Africa or India, where I just returned from. Secondly, we screen whether the product has compelling financial prospects. Fortunately, if a product fails this second test, but we find it sufficiently compelling in terms of the first, we can send the opportunity to our colleagues at the Gates Foundation, who can pick up low-return but high-impact projects.”

https://www.google.co.uk/amp/s/www.forbes.com/sites/kevinharris/2019/04/09/how-the-gates-foundation-is-revolutionizing-global-health-impact-investing/amp/

I’m really not sure - but interesting angle to explore, thoughts?

PP